The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...
Verywell Health on MSN1d
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant DepressionPeople with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...
ScienceAlert on MSN6d
FDA-Approved Nasal Spray For Depression Is First Of Its KindA ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment ... communities about the difference between esketamine versus ketamine, and whether esketamine ...
(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback